ArticleBMC rheumatology2020
Views of primary care physicians and rheumatologists regarding screening and treatment of hyperlipidemia among patients with rheumatoid arthritis.
Article in BMC rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Exploring cardiovascular risk management implementation in Dutch rheumatoid arthritis patients: insights from rheumatologists and patients.Rheumatology advances in practice · 2026Article
- Atherosclerotic cardiovascular disease in systemic lupus erythematosus: from preclinical lupus to atherosclerotic plaque erosion.Rheumatology advances in practice · 2025Review
- A study of lipid profile peculiarities and atherogenic index of plasma in patients younger than fifty years of age with newly diagnosed rheumatoid arthritis.Journal of family medicine and primary care · 2025Article
- Cardio-Rheumatology Insights Into Hypertension: Intersection of Inflammation, Arteries, and Heart.American journal of hypertension · 2024Review
- Cardiovascular disease risk assessment in patients with rheumatoid arthritis: A scoping review.Clinical rheumatology · 2024Article
- Management of Rheumatoid Arthritis in Primary Care: A Scoping Review.International journal of environmental research and public health · 2024Article
- The use of virtual nominal groups in healthcare research: An extended scoping review.PloS one · 2024Article
- Cardiovascular manifestations and comorbidities in rheumatic diseases: perspectives on timely diagnosis, prevention, and treatment.Clinical rheumatology · 2023Article
- Virtual training of rheumatoid arthritis peer coaches in motivational interviewing skills and concepts of cardiovascular disease.Contemporary clinical trials communications · 2023Article
- Protocol for the pilot randomized trial of the CArdiovascular Risk assEssment for Rheumatoid Arthritis (CARE RA) intervention: a peer coach behavioral intervention.Pilot and feasibility studies · 2022Article
- Comment on: Lipid screening and statins alongside disease-modifying anti-rheumatic drugs for patients with rheumatoid arthritis: reply.Rheumatology (Oxford, England) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundDespite high risk for cardiovascular disease (CVD) mortality, screening and treatment of hyperlipidemia in patients with rheumatoid arthritis (RA) is suboptimal. We asked primary care physicians (PCPs) and rheumatologists to identify barriers to screening and treatment for hyperlipidemia among patients with RA.
methodsWe recruited rheumatologists and PCPs nationally to participate in separate moderated structured group teleconference discussions using the nominal group technique. Participants in each group generated lists of barriers to screening and treatment for hyperlipidemia in patients with RA, then each selected the three most important barriers from this list. The resulting barriers were organized into physician-, patient- and system-level barriers, informed by the socioecological framework.
resultsTwenty-seven rheumatologists participated in a total of 3 groups (group size ranged from 7 to 11) and twenty PCPs participated in a total of 3 groups (group size ranged from 4 to 9). Rheumatologists prioritized physician level barriers (e.g. 'ownership' of hyperlipidemia screening and treatment), whereas PCPs prioritized patient-level barriers (e.g. complexity of RA and its treatments).
conclusionRheumatologists were conflicted about whether treatment of CVD risk among patients with RA should fall within the role of the rheumatologist or the PCP. All participating PCPs agreed that CVD risk reduction was within their role. Factors that influenced PCPs' decisions for screening and treatment for CVD risk in patients with RA were mainly related to their concern about how treatment for CVD risk could influence RA symptomatology (myalgia from statins) or how inflammation from RA and RA medications influences lipid profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.